Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Hold" by Brokerages

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have earned an average rating of "Hold" from the eight brokerages that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.78.

A number of research firms recently weighed in on IRWD. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Craig Hallum cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Leerink Partners cut their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a report on Monday, April 14th. Jefferies Financial Group restated a "hold" rating and set a $0.70 target price (down from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday, April 15th. Finally, Wells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 price target (down previously from $7.00) on shares of Ironwood Pharmaceuticals in a research note on Tuesday, April 15th.

Ironwood Pharmaceuticals Stock Down 2.9%

Ironwood Pharmaceuticals stock opened at $0.77 on Friday. The business's 50-day simple moving average is $0.68 and its 200 day simple moving average is $1.50. The stock has a market cap of $124.20 million, a price-to-earnings ratio of -3.84 and a beta of 0.30. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $7.11.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.09). The company had revenue of $41.14 million during the quarter, compared to the consensus estimate of $67.02 million. Ironwood Pharmaceuticals had a negative net margin of 9.89% and a negative return on equity of 1.87%. As a group, sell-side analysts expect that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Large investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $36,000. Envestnet Asset Management Inc. purchased a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth approximately $50,000. Xponance Inc. bought a new position in Ironwood Pharmaceuticals during the 4th quarter valued at approximately $50,000. Boothbay Fund Management LLC purchased a new position in Ironwood Pharmaceuticals during the fourth quarter valued at $57,000. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in Ironwood Pharmaceuticals in the fourth quarter worth $59,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.